Dietary antioxidants and Parkinson disease: The Rotterdam Study

Archives of Neurology

Volumn 54, Issue 6, 1997, Pages 762-765

  De Rijk, Maarten C ^a   Breteler, Monique M B ^a   Den Breeijen, Johanna H ^a   Launer, Lenore J ^a   Grobbee, Diederick E ^a   Van der Meche, Frans G A ^a   Hofman, Albert ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; FLAVONOID; VITAMIN;

ADULT; AGED; ARTICLE; DIETARY INTAKE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPROTECTION; NUTRITIONAL HEALTH; PARKINSON DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; VITAMIN INTAKE;

EID: 0030943863     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1997.00550180070015     Document Type: Article

References (42)

1. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neural. 1992;32:804-812.
2. Jenner P, Dexter DT, Sian J, Schapira AH, Marsden CD. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. Ann Neurol. 1992;32(suppl):S82-S87.
3. Jenner P. Oxidative damage in neurodegenerative disease. Lancet. 1994;344: 796-798.
4. DATATOP: a multicenter, controlled clinical trial in early Parkinson's disease. Arch Neurol. 1989;46:1052-1060.
5. Logroscino G, Marder K, Cote L, Tang M-X, Shea S, Mayeux R. Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann Neurol. 1996;39:89-94.
6. Morens DM, Grandinetti A, Waslien CI, Park CB, Ross GW, White LR. Case- control study of idiopathic Parkinson's disease and dietary vitamin E intake. Neurology. 1996;46:1270-1274.
7. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol. 1991;7:403-422.
8. van den Brandt PA, Goldbohm RA, van 't Veer P, Volovics A, Hermus RJ, Sturmans F. A large-scale prospective cohort study on diet and cancer in The Netherlands. J Clin Epidemiol. 1990;43:285-295.
9. Ott A, Breteler MMB, van Harskamp F, et al. Prevalence of Alzheimer's disease and vascular dementia: association with education-the Rotterdam Study. BMJ. 1995;310:970-973.
10. Dutch Food Composition Table 1993. The Hague, the Netherlands: Voorlichtingsbureau voor de Voeding; 1993.
11. de Rijk MC, Breteler MMB, Graveland GA, et al. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology. 1995;45:2143-2146.
12. Fahn S, Elton RL, and the UPDRS Development Committee. Unified Parkin son's disease rating scale. In: Fahn S, Marsden CD, Calne DB, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: Macmillan Healthcare Information; 1987:153-163.
13. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality, Neurology. 1967;17:427-442.
14. Willett W, Stampfer MJ. Total energy intake: implications for epidemiologic analyses. Am J Epidemiol. 1986;124:17-27.
15. Goldbohm RA, van 't Veer P, van den Brandt PA, et al. Reproducibility of a food frequency questionnaire and stability of dietary habits determined from five annually repeated measurements. Eur J Clin Nutr. 1995;49:420-429.
16. Sian J, Dexter DT, Lees AJ, et al. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol. 1994;36:348-355.
17. Dexter DT, Wells FR, Agid F, et al. Increased nigral iron content in postmortem parkinsonian brain. Lancet. 1987;2:1219-1220.
18. Dexter DT, Wells FR, Lees AJ, et al. Increased nigral iron content and alterations in other metal ions occurring in the brain in Parkinson's disease. J Neurochem. 1989;52:1830-1836.
19. Saggu H, Cooksey J, Dexter D, et al. A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem. 1989; 53:692-697.
20. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem. 1990; 54:823-827.
21. Schapira AH. Mitochondrial complex I deficiency in Parkinson's disease. Adv Neurol. 1993;60:288-291.
22. Haas R, Nasirian F, Nakano K, et al. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann Neurol. 1995; 37:714-722.
23. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem. 1989;52:381-389.
24. Dexter DT, Holley AE, Flitter WD, et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord. 1994;9:92-97.
25. Golbe LI, Farrell TM, Davis PH. Case-control study of early life dietary factors in Parkinson's disease. Arch Neurol. 1988;45:1350-1353.
26. Golbe LI, Farrell TM, Davis PH. Follow-up study of early-life protective and risk factors in Parkinson's disease. Mov Disord. 1990;5:66-70.
27. King D, Playfer JR, Roberts NB. Concentrations of vitamins A, C and E in elderly patients with Parkinson's disease. Postgrad Med J. 1992;68:634-637.
28. Hellenbrand W, Seidler A, Boeing H, et al. Diet and Parkinson's disease, II: a possible role for the past intake of specific nutrients-results from a self- administered food-frequency questionnaire in a case-control study. Neurology. 1996;47:644-650.
29. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engt J Med. 1993;328:176-183.
30. Marsden CD. Parkinson's disease. Lancet. 1990;335:948-952.
31. Scherman D, Desnos C, Darchen F, Pollak P, Javoy-Agid F, Agid Y. Striatal dopamine deficiency in Parkinson's disease: role of aging. Ann Neurol. 1989; 26:551-557.
32. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114:2283-2301.
33. Lee CS, Schulzer M, Mak EK, et al. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain. 1994;117:501-507.
34. 18F-fluorodopa uptake and disease progression in Parkinson's disease. Neurology. 1995;45(suppl):A220.
35. 18F]dopa PET findings in early Parkinson's disease. J Neurol Neurosurg Psychiatry. 1995;59:597-600.
36. Burton GW, Ingold KU. Beta-carotene: an unusual type of lipid antioxidant. Science. 1984;224:569-573.
37. Fernandez CP, Jimenez JF, Molina JA, et al. Serum levels of ascorbic acid (vitamin C) in patients with Parkinson's disease. J Neuroi Sci. 1993;118:25-28.
38. Jimenez JF, Molina JA, Fernandez CP, et al. Serum levels of vitamin A in Parkinson's disease. J Neuroi Sci. 1992;111:73-76.
39. Jimenez JF, Molina JA, Fernandez CP, et al. Serum levels of beta-carotene and other carotenoids in Parkinson's disease. Neurosci Lett. 1993;157:103-106.
40. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet. 1993;342:1007-1011.
41. Rimm EB, Katan MB, Ascherio A, Stampfer MJ, Willet WC. Relation between intake of flavonoids and risk of coronary heart disease in male health professionals. Ann Intern Med. 1996;125:384-389.
42. Sorata Y, Takahama U, Kimura M. Protective effect of quercetin and rutin on photosensitized lysis of human erythrocytes in the presence of hematoporphyrin. Biochim Biophys Acta. 1984;799:313-317.